Christina Louise Rasmussen

Christina Louise Rasmussen

Auto-generated profile, based on publicly available information

Christina Louise Rasmussen

Unit of Virus, Lifestyle and Genes, Danish Cancer Society Research Center, Copenhagen, Denmark

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 November 2017 in International Journal of Cancer
Verified
Journal Article
Closed access
PDF file
CRChristina Louise Rasmussen
Christina Louise Rasmussen
FSFreja Lærke Sand
Freja Lærke Sand
MFMarie Hoffmann Frederiksen
Marie Hoffmann Frederiksen
KAKlaus Kaae Andersen
Klaus Kaae Andersen
SKSusanne K. Kjaer
Susanne K. Kjaer

18 December 2018 in International Journal of Cancer
Verified
Journal Article
Closed access
PDF file
HBHanna Kristina Bertoli
Hanna Kristina Bertoli
CRChristina Louise Rasmussen
Christina Louise Rasmussen
FSFreja Lærke Sand
Freja Lærke Sand
VAVanna Albieri
Vanna Albieri
BNBodil Norrild
Bodil Norrild
SKSusanne K. Kjaer
Susanne K. Kjaer

1 April 2020 in Cancer Epidemiology, Biomarkers & Prevention
Verified
Journal Article
Closed access
PDF file
AUAivara Urbute
Aivara Urbute
CRChristina Louise Rasmussen
Christina Louise Rasmussen
FBFederica Belmonte
Federica Belmonte
TOTheresa Obermueller
Theresa Obermueller
EPElena-Sophie Prigge
Elena-Sophie Prigge
SKSusanne K. Kjaer
Susanne K. Kjaer
We conducted a systematic review and meta-analysis of observational studies evaluating survival in patients with anal cancer, according to human papillomavirus (HPV) DNA, p16INK4a, and combined HPV DNA/p16INK4a status. We systematically searched PubMed, EMBASE, and Cochrane Library databases to identify studies published in English until July 25, 2018, directly providing or allowing estimation of survival of patients with anal cancer according to the presence of HPV DNA and/or overexpression of p16INK4a. We estimated pooled HRs and 95% confidence intervals (CI) for overall survival (OS) using a random-effects model. We included 16 studies, comprising 1,724 patients with anal cancer tested for HPV DNA (65% positive), and 567 patients tested for p16INK4a (87% positive). The pooled HR for OS was 0.54 (95% CI, 0.33–0.89) for HPV DNA positive versus negative, 0.37 (95% CI, 0.24–0.57) for p16INK4a positive versus negative, and 0.36 (95% CI, 0.22–0.58) for HPV DNA positive/p16INK4a positive versus HPV DNA positive/p16INK4a negative patients with anal cancer. Patients with HPV DNA or p16INK4a positive anal cancer have significantly better OS compared with HPV DNA or p16INK4a negative. This points to the possible value of HPV DNA and/or p16INK4a testing when planning the management and follow-up strategy for patients diagnosed with anal cancer.

21 September 2021 in Acta Obstetricia et Gynecologica Scandinavica
Verified
Journal Article
Open access
PDF file
CRChristina L. Rasmussen
Christina L. Rasmussen
HBHanna K. Bertoli
Hanna K. Bertoli
FSFreja L. Sand
Freja L. Sand
AKAlexander K. Kjær
Alexander K. Kjær
LTLouise T. Thomsen
Louise T. Thomsen
SKSusanne K. Kjaer
Susanne K. Kjaer
Introduction: Human papillomavirus (HPV), p16, and p53 have been investigated as prognostic markers in various HPV‐related cancers. Within the field of vaginal cancer, however, the evidence remains sparse. In this systematic review, we have compiled the presently published studies on the prognostic significance of HPV and immunohistochemical expression of p16 and p53 among women with vaginal cancer.Material and methods: We conducted a systematic search of PubMed, Embase, and Cochrane Library to identify relevant studies published until April 2021. We included studies reporting survival after histologically verified vaginal cancers tested for HPV, p16, and/or p53. Survival outcomes included overall survival, disease‐free survival, disease‐specific survival, and progression‐free survival.Results: We included a total of 12 studies. The vast majority of vaginal cancer cases included in each study were squamous cell carcinomas (84%–100%). Seven studies reported survival after vaginal cancer according to HPV status, and the majority of these studies found a tendency towards improved survival for women with HPV‐positive vaginal cancer. Three out of four studies reporting survival according to p16 status found an improved survival among women with p16‐positive vaginal cancer. For p53, only one of six studies reported an association between p53 expression and survival.Conclusions: This systematic review suggests that women with HPV‐ and p16‐positive vaginal cancer have an improved prognosis compared with those with HPV‐ or p16‐negative vaginal cancer. Results for p53 were varied, and no conclusion could be reached. Only 12 studies could be included in the review, of which most were based on small populations. Hence, further and larger studies on the prognostic impact of HPV, p16, and p53 in vaginal cancer are warranted.

1 June 2020 in Gynecologic Oncology
Verified
Journal Article
Closed access
CRChristina Louise Rasmussen
Christina Louise Rasmussen
LTLouise T. Thomsen
Louise T. Thomsen
GAGitte Lerche Aalborg
Gitte Lerche Aalborg
SKSusanne K. Kjaer
Susanne K. Kjaer

1 November 2021 in European Journal of Cancer
Verified
Journal Article
Closed access
TOTheresa Obermueller
Theresa Obermueller
JHJoris Hautekiet
Joris Hautekiet
MBMaria P. Busto
Maria P. Busto
DRDries Reynders
Dries Reynders
LBLiliana Belgioia
Liliana Belgioia
EPElena-Sophie Prigge
Elena-Sophie Prigge